Advertisement

Topics

Mepsevii Approved for Rare Enzyme Disorder

08:31 EST 15 Nov 2017 | Drugs.com

WEDNESDAY, Nov. 15, 2017 -- Mepsevii (vestronidase alfa-vjbk) has been approved by the U.S. Food and Drug Administration to treat a rare, genetic disorder called mucopolysaccharidosis type VII, sometimes called Sly syndrome. Affecting fewer than 150...

Original Article: Mepsevii Approved for Rare Enzyme Disorder

NEXT ARTICLE

More From BioPortfolio on "Mepsevii Approved for Rare Enzyme Disorder"

Advertisement
Quick Search
Advertisement
Advertisement